PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER Solicitation ID/Procurement Identifier: 75N91019D00020 Ultimate Completion Date: Sun Sep 15 17:00:00 GMT 2024
PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM Solicitation ID/Procurement Identifier: 75N91023R00024 Ultimate Completion Date: Wed Jan 24 18:00:00 GMT 2029
See attached for a copy of the Justification and Approval document to increase the stated maximum dollar value (programmatic ceiling) for the following contracts: 75N91019D00012, 75N91019D00013, 75N91019D00014, 75N91019D00015, 75N91019D00016, 75N91019D00017, 75N91019D00018, 75N91019D00020, 75N91019D00021, 75N91019D00022, 75N91019D00025, and 75N91019D00026.
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: TOXICOLOGY AND PHARMACOLOGY TESTING Solicitation ID/Procurement Identifier: 75N91023R00024 Ultimate Completion Date: Wed Jan 24 18:00:00 GMT 2029
Each development program operates in a multi-disciplinary matrix team environment, with a DPI project officer (PO) responsible for overall planning, execution, and reporting.Information RequestedThe Government seeks to obtain information about industry capabilities to support the DPI drug development programs by providing Chemistry, Manufacturing, and Control (CMC) services.
The overall objective of the current acquisition is to provide a structured approach to drug and vaccine development, from discovery to the clinic.
Toward the accomplishment of that mission, the PREVENT Cancer Preclinical Drug Development Program (PREVENT) was instituted in 2012 to Provide a structured approach to drug and vaccine development, from discovery to the clinic.
